TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7993599

Group type: EXPERIMENTAL
Intervention: Sealants applied with a drying agent
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sealants applied without a drying agent
Number of subjects: 28
Study: 2525377

Group type: EXPERIMENTAL
Intervention: Preservative-free ipratropium bromide
Number of subjects: 33

Group type: COMPARATOR
Intervention: Preservative-containing ipratropium bromide
Number of subjects: 33
Study: 4881341

Group type: EXPERIMENTAL
Intervention: Aqueous vasopressin injection (Pitressin)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study: 31177180

Group type: EXPERIMENTAL
Intervention: Lower glycated hemoglobin targets (6.5‐7.0%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher glycated hemoglobin targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modification of target levels based on clinical experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose control over 5 years or more
Number of subjects: 0
Study: 29637896

Group type: EXPERIMENTAL
Intervention: Mg lactate (MgLact2) supplementation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Potassium citrate (K3Citrate) for high UpH
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ammonium chloride (NH4Cl) for low UpH
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alkali load (KCl)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mg supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: High UpH vs Low UpH
Number of subjects: 8
Study: 25952160

Group type: EXPERIMENTAL
Intervention: Family-based behavioral intervention integrating motivational interviewing, active learning, and applied problem-solving.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control condition with equivalent assessments and number of contacts without dietary advice.
Number of subjects: 136
Study: 22134732

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 65

Group type: COMPARATOR
Intervention: Antiresorptive agents combined with repeated PVPs
Number of subjects: 65
Study: 21197525

Group type: EXPERIMENTAL
Intervention: High-fluence, single-pass diode laser
Number of subjects: 22

Group type: COMPARATOR
Intervention: Low-fluence, multiple-pass diode laser
Number of subjects: 22
Study: 19920001

Group type: EXPERIMENTAL
Intervention: Revascularization plus intensive medical therapy
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Intensive medical therapy alone
Number of subjects: 2368

Group type: EXPERIMENTAL
Intervention: Insulin sensitization
Number of subjects: 2368

Group type: COMPARATOR
Intervention: Insulin provision therapy
Number of subjects: 2368
Study: 17023284

Group type: EXPERIMENTAL
Intervention: Pulsatile waveform transduced through an epidural needle
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Epidural catheters
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Group S‐P/Sims Portex catheters
Number of subjects: 81
Study: 14632623

Group type: EXPERIMENTAL
Intervention: Pain Group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Non-pain Group
Number of subjects: 44
Study: 10989990

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 32
Study: 9868028

Group type: EXPERIMENTAL
Intervention: Musical relaxation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 0
Study: 8347328

Group type: EXPERIMENTAL
Intervention: Ceranapril
Number of subjects: 0
Study: 3646613

Group type: EXPERIMENTAL
Intervention: Self-administered pain medication
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nurse-administered pain medication
Number of subjects: 64
Study: 31480865

Group type: EXPERIMENTAL
Intervention: Smartphone-assisted technique (n=32)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional technique (n=32)
Number of subjects: 64
Study: 31848443

Group type: EXPERIMENTAL
Intervention: Body-weight supported locomotor training (BWSLT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 37
Study: 29940151

Group type: EXPERIMENTAL
Intervention: Intensive treatment arm (blood pressure target <= 120 mmHg)
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Control arm (blood pressure target <= 140 mmHg)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Pulse pressure increase (every 10 mmHg)
Number of subjects: 9361

Group type: EXPERIMENTAL
Intervention: Combined effect of pulse pressure and treatment intensity
Number of subjects: 9361
Study: 29121884

Group type: EXPERIMENTAL
Intervention: Theory-based physical activity intervention
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 152
Study: 25137430

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine continuous infusion at a rate of 0.4 μg kg(‐1) hour(‐1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Physiologic saline infusion
Number of subjects: 68
Study: 23393099

Group type: EXPERIMENTAL
Intervention: Culturally targeted patient navigation delivered by a professional navigator (Pro-PN)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Culturally targeted patient navigation delivered by a community-based peer navigator (Peer-PN)
Number of subjects: 315
Study: 21412761

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Non-users of SBRT
Number of subjects: 1373
Study: 18241321

Group type: EXPERIMENTAL
Intervention: XR‐NTX 380 mg
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: XR‐NTX 190 mg
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 16796717

Group type: EXPERIMENTAL
Intervention: Pulse corticosteroid therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: No protocol biopsies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biopsies only in high-risk recipients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Universal screening protocol biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased baseline immunosuppression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized clinical trial of biopsy and corticosteroid therapy
Number of subjects: 0
Study: 14743949

Group type: EXPERIMENTAL
Intervention: Specialist (S) model
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Practitioner (P) model
Number of subjects: 4
Study: 10693903

Group type: EXPERIMENTAL
Intervention: Group psychosocial support intervention
Number of subjects: 652
Study: 9020413

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 10 mg plus terbutaline 0.5 mg (group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo plus terbutaline 0.5 mg (group B)
Number of subjects: 62
Study: 1413302

Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate, 80 mg, administered 8-hourly for a total of three doses, starting just prior to the operation
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no gentamicin prophylaxis)
Number of subjects: 110
Study: 4042543

Group type: EXPERIMENTAL
Intervention: Alcohol (0.9 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (400 ml of orange juice)
Number of subjects: 8
Study: 31206016

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) for 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg) for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls (not specified)
Number of subjects: 0
Study: 29237386

Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acids
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: nano‐curcumin
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Combination of ω‐3 fatty acids and nano‐curcumin
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 26871968

Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days with left lateral horizontal position for 30 min after dosing (GS group 1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate (220 mg), esomeprazole (20 mg), amoxicillin (1.0 g), and furazolidone (100 mg) twice daily for 14 days (GS group 2)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (non-gastrectomized patients)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All groups (including GS group 1 and GS group 2)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study: 25521726

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Teprenone 150 mg/day
Number of subjects: 66
Study: 22354457

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study: 20849620

Group type: EXPERIMENTAL
Intervention: 8 or 16 fluid ounces of vegetable juice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 fluid ounces of vegetable juice daily (Control)
Number of subjects: 0
Study: 17761704

Group type: EXPERIMENTAL
Intervention: EC (epirubicin/cyclophosphamid)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Dose intensified E (epirubicin) followed by taxane
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: CMF (cyclophosphamid/methorexate/fluorouracil)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Initial response of CETC
Number of subjects: 58
Study: 15755847

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment (n = 99; initial dose 8 microg/kg)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo (n = 97)
Number of subjects: 196
Study: 16515992

Group type: EXPERIMENTAL
Intervention: Positive family history screening
Number of subjects: 1364

Group type: COMPARATOR
Intervention: Sporadic cases screening
Number of subjects: 1364

Group type: EXPERIMENTAL
Intervention: Overall biochemical-free survival rate
Number of subjects: 1364
Study: 10665102

Group type: EXPERIMENTAL
Intervention: Public health efforts to prompt cessation in half the communities
Number of subjects: 1410
Study: 8880018

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 620
Study: 2012585

Group type: EXPERIMENTAL
Intervention: Creative novation behaviour therapy (long-term individual therapy, group therapy, bibliotherapy plus short-term individual treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoanalysis
Number of subjects: 0
Study: 6665837

Group type: EXPERIMENTAL
Intervention: Tinidazole (40 mg/kg body-weight in one daily dose for five days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tinidazole plus diloxanide furoate (tinidazole at 40 mg/kg body-weight in one daily dose for five days and diloxanide furoate at 20 mg/kg body-weight divided into three daily doses for 10 days)
Number of subjects: 0
Study: 31486981

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30051499

Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.75 mg/d
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control (no extra treatment)
Number of subjects: 459
Study: 26018749

Group type: EXPERIMENTAL
Intervention: ACLS training module: Laerdal® ALS Skillmaster
Number of subjects: 30
Study: 25033789

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 1200 mg/day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ginseng 200 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 48
Study: 22441301

Group type: EXPERIMENTAL
Intervention: aranidipine 5-10 mg/d (n = 118)
Number of subjects: 236

Group type: COMPARATOR
Intervention: amlodipine 5-10 mg/d (n = 118)
Number of subjects: 236
Study: 20122576

Group type: EXPERIMENTAL
Intervention: Chronic treatment with statins for at least 6 months (group B)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No treatment with statins (group A)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 103
Study: 17415136

Group type: EXPERIMENTAL
Intervention: Tonsillotomy (TT) with radiosurgery (RF)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Cold tonsillectomy (TE)
Number of subjects: 114
Study: 16118720

Group type: EXPERIMENTAL
Intervention: AmniSure rapid immunoassay
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard diagnostic methods
Number of subjects: 203
Study: 12165574

Group type: EXPERIMENTAL
Intervention: TRH (400 micro g every 8 hours up to 4 doses)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 10064126

Group type: EXPERIMENTAL
Intervention: Hormone analogue (2.5 mg Livial) plus 800 mg calcium
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo plus 800 mg calcium
Number of subjects: 33
Study: 7495600

Group type: COMPARATOR
Intervention: Moderately active participants
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Very active participants
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Sedentary participants
Number of subjects: 2004
Study: 31873286

Group type: EXPERIMENTAL
Intervention: Population activity decoding of likelihood function from visual cortex during categorization task
Number of subjects: 0
Study: 30935369

Group type: EXPERIMENTAL
Intervention: TSEipcw (Two-stage estimation with inverse probability of censoring weights)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Re-censoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-re-censoring
Number of subjects: 0
Study: 27855463

Group type: EXPERIMENTAL
Intervention: Obese women (339)
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Class 3 obese women (69)
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Nonobese women (1261)
Number of subjects: 1669
Study: 25573070

Group type: EXPERIMENTAL
Intervention: Stochastic Vestibular Stimulation (SVS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: LDOPA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SVS combined with LDOPA
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 10
Study: 23711727

Group type: EXPERIMENTAL
Intervention: Assistive Listening Device (ALD) during structured conversation task
Number of subjects: 22

Group type: COMPARATOR
Intervention: No Assistive Listening Device (ALD) during structured conversation task
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Normal-hearing groups
Number of subjects: 22

Group type: COMPARATOR
Intervention: Self-perceived hearing handicap
Number of subjects: 22
Study: 21350719

Group type: EXPERIMENTAL
Intervention: Fast-track rehabilitation program
Number of subjects: 210

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 210
Study: 18611062

Group type: COMPARATOR
Intervention: Aripiprazole 15 mg (hepatic impairment study)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Aripiprazole 15 mg (renal impairment study)
Number of subjects: 38
Study: 16038680

Group type: EXPERIMENTAL
Intervention: 2-deoxy-D-glucose (inducing a mild state of glucoprivation)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 96
Study: 12509164

Group type: EXPERIMENTAL
Intervention: Landmark condition; route learning with landmarks
Number of subjects: 84

Group type: COMPARATOR
Intervention: No-Landmark condition; route learning with no landmarks
Number of subjects: 84
Study: 10591309

Group type: COMPARATOR
Intervention: Methylphenidate (Ritalin) hydrochloride at doses of 0.3 mg/kg or 0.6 mg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8901800

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (50 mg on alternate days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 59
Study: 1831585

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus followed by 2.5 micrograms/kg/min maintenance infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus followed by 5.0 micrograms/kg/min maintenance infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone 0.5 mg/kg bolus followed by 10.0 micrograms/kg/min maintenance infusion
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Enoximone 5.0 micrograms/kg/min maintenance infusion without loading dose
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All groups receiving enoximone
Number of subjects: 21
Study: 6344645

Group type: EXPERIMENTAL
Intervention: Orthokeratological (OK) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31651592

Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy
Number of subjects: 310

Group type: COMPARATOR
Intervention: Office-based placebo therapy
Number of subjects: 310
Study: 30630804

Group type: EXPERIMENTAL
Intervention: Controlled hypotension Group 1 (Group H1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Controlled hypotension Group 2 (Group H2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Normal blood pressure Group (Group N)
Number of subjects: 75
Study: 26526816

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stents (SES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Everolimus‐eluting stents (EES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting stents (ZES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 24292216

Group type: EXPERIMENTAL
Intervention: Endoscope-assisted surgery
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 22426327

Group type: COMPARATOR
Intervention: Human EV71 vaccine (200 U and 400 U for adults and children; 100 U, 200 U, and 400 U for infants); administered intramuscularly on Days 0, 14, and 28 for adults, and Days 0, 28, and 56 for children and infants.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo; administered in the same schedule as the vaccine.
Number of subjects: 0
Study: 18722511

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (preventive antibacterial therapy)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 18560142

Group type: EXPERIMENTAL
Intervention: Telerehabilitation system
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional face-to-face assessment
Number of subjects: 12
Study: 16104989

Group type: EXPERIMENTAL
Intervention: Valacyclovir (n=43)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Oral ganciclovir (n=40)
Number of subjects: 83
Study: 12401624

Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine/fentanyl 5 micro g/mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine/fentanyl 5 micro g/mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 80

Group type: COMPARATOR
Intervention: IV morphine consumption
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pain scores (rest and spirometry)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Motor block
Number of subjects: 80
Study: 10405061

Group type: EXPERIMENTAL
Intervention: Delfon
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Conceptrol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Advantage 24
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: VCF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Semicid
Number of subjects: 10
Study: 7545449

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Titrarine (Stago) and Heptest (Haemachem)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Thrombin time
Number of subjects: 26
Study: 2208619

Group type: EXPERIMENTAL
Intervention: Oxibendazole 15mg/kg.d x 3d
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Pyrantel 10mg/kg.d x 3d
Number of subjects: 714

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study: 6107232

Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg iv
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg po
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Furosemide (iv and po)
Number of subjects: 9
Study: 31692248

Group type: EXPERIMENTAL
Intervention: Randomization for data visualization
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dimensional analytical tools (dimensionality reduction, clustering, network reconstruction)
Number of subjects: 0
Study: 29985762

Group type: EXPERIMENTAL
Intervention: Fourier transform infrared (FT-IR) analysis
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Calibration of FT-IR analysis
Number of subjects: 75

Group type: COMPARATOR
Intervention: Traditional laboratory X-ray diffraction (XRD) analysis
Number of subjects: 75
Study: 26139093

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30 min twice a week)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study: 25311600

Group type: COMPARATOR
Intervention: Very early adiposity rebound (AR) (by 3.5 years)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Early adiposity rebound (AR) (between 3.5 and 5 years)
Number of subjects: 546
Study: 22079079

Group type: EXPERIMENTAL
Intervention: 5%, 10%, 15%, or 20% W(80)5EC combined with 4 or 10 μg strain‐specific Fluzone(®) HA
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 20% W(80)5EC combined with 10 μg strain‐specific HA
Number of subjects: 199

Group type: COMPARATOR
Intervention: Intranasal PBS
Number of subjects: 199

Group type: COMPARATOR
Intervention: Intranasal Fluzone(®)
Number of subjects: 199

Group type: COMPARATOR
Intervention: 15 μg strain‐specific intramuscular Fluzone(®)
Number of subjects: 199
Study: 20580029

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) - conjugated equine estrogen 0.625 mg/d with or without medroxyprogesterone acetate 2.5 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study: 17610100

Group type: EXPERIMENTAL
Intervention: 2 g/day CLA plus 2 g/day SFO
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4 g/day CLA
Number of subjects: 12

Group type: COMPARATOR
Intervention: 4 g/day safflower oil (SFO)
Number of subjects: 12